Skip to content

A clinical trial to evaluate the effect of improving allergy-like symptoms: A randomized controlled trial.

A clinical trial to evaluate the effect of improving allergy-like symptoms: A randomized controlled trial. - A clinical trial to evaluate the effect of improving allergy-like symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016220
Enrollment
60
Registered
2015-01-15
Start date
2015-01-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 8 weeks Test material: Shiitake mycelium extract powder Usage and Dose: 4 capsules/day (after breakfast and after dinner, each 2 capsules with water or plain hot water.) Duration: 8 week

Sponsors

ORTHOMEDICO, Inc.
Lead Sponsor
Seishin-kai Medical Association Inc, Takara Medical Clinic.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy adults, who suffer from allergy-like symptoms

Exclusion criteria

Exclusion criteria: a.Persons who have previous medical history of malignant tumor or heart failure or myocardial infarction b.Patients being treated for at least one of following diseases atrial fibrillation, cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension and other chronic disease c.Persons who take medicines, herbal medicines, supplements related to test food. d.Persons who take foods/drinks expected to be related with gut health, such as Food for Specified Health Uses (FOSHU), yogurt and, lactic fermenting beverage e.Persons who are allergic to medicines, or products related to the test material of this trial f. Persons who have been judged as pollinosis by doctors g.Pregnant women, lactating women, or women who want to get pregnant during the trial period h.Persons who have been enrolled in the other clinical trials within last 3 months before the agreement for the participation to this trial i.Persons who are judged not suitable to participate in this trial by physician

Design outcomes

Primary

MeasureTime frame
[JRQLQ] nasal symptom ophthalmic symptom QOL question

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO, Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026